Sarcoidosis: The Disease That Mimics Everything Else — and Is Missed for Years
Sarcoidosis is one of medicine's great mimics — producing symptoms that look like tuberculosis, lymphoma, or a dozen other conditions. A pulmonologist explains what sarcoidosis actually is, why it is so often misdiagnosed in Pakistan, how to tell it apart from TB, and what modern treatment looks like.
There is a condition I see regularly in my clinic that has, in most cases, already been treated for something else before the patient reaches me. They have completed a full course of anti-tuberculosis therapy — six months of medication — for a diagnosis that was never confirmed by culture or GeneXpert, based only on a chest X-ray showing enlarged lymph nodes and a positive tuberculin skin test. The TB treatment did not help. The lymph nodes are still enlarged. The breathlessness has not improved. And now, finally, someone has thought to look beyond TB.
Sarcoidosis — a chronic inflammatory condition characterised by the formation of granulomas in multiple organs — is one of the most under-recognised diseases in Pakistan. Not because it is rare, but because its most common manifestation in the lungs and lymph nodes is virtually indistinguishable from tuberculosis on basic clinical assessment and chest X-ray. In a country with very high TB prevalence, the automatic assumption that enlarged mediastinal lymph nodes plus granulomatous inflammation equals TB is a clinical reflex that, while understandable, misses sarcoidosis in a significant proportion of patients every year.
Those patients deserve the correct diagnosis. And they deserve it earlier. This article is for them — and for the clinicians, family members, and patients who have been through the frustration of a diagnosis that did not fit, a treatment that did not work, and a condition that nobody adequately explained.
What Is Sarcoidosis?
Sarcoidosis is a chronic systemic inflammatory disease characterised by the formation of granulomas — small, compact clusters of inflammatory cells — in affected organs. Granulomas form when the immune system mounts an exaggerated response to an antigen it cannot clear. In sarcoidosis, the triggering antigen has never been definitively identified — candidates include mycobacterial antigens, propionibacterial antigens, and various environmental exposures — but the immune response, once triggered, produces granulomas that can appear in virtually any organ of the body.
The lungs and mediastinal lymph nodes are affected in approximately 90 percent of cases, making pulmonary sarcoidosis the predominant clinical presentation. But sarcoidosis can simultaneously or independently affect the skin, eyes, liver, spleen, heart, nervous system, kidneys, and bones — and it is this multisystem involvement that gives the condition its reputation as "the great imitator."
Understanding what sarcoidosis is — and crucially, what it is not — requires grasping a key pathological distinction. In tuberculosis, granulomas form in response to a specific living organism (Mycobacterium tuberculosis) that can be identified, cultured, and treated with antibiotics. In sarcoidosis, no organism is present — the granulomas form in response to an immune dysregulation whose trigger has not been identified, and they are not infectious, not transmissible, and not treated with antibiotics. Treating sarcoidosis with anti-TB drugs does not help — and the months or years spent on unnecessary TB treatment delay the correct diagnosis and the treatment that would actually benefit the patient.
What Causes Sarcoidosis?
The honest answer is that the precise cause of sarcoidosis remains unknown — a fact that frustrates patients who want a clear explanation for why their immune system behaved this way. What research has established is a framework of contributing factors rather than a single cause.
Immune Dysregulation
Sarcoidosis is fundamentally a disease of immune dysregulation. In affected patients, the immune system mounts an exaggerated Th1-type inflammatory response to an environmental trigger — producing granulomas that, in most patients, eventually resolve spontaneously, but in a significant minority persist, coalesce, and cause progressive organ damage through fibrosis.
Genetic Predisposition
Sarcoidosis clusters in families — first-degree relatives of affected patients have a fivefold higher risk of developing the condition. Several HLA gene variants have been associated with both susceptibility to sarcoidosis and with specific clinical phenotypes — certain genetic backgrounds are associated with more severe disease and a lower rate of spontaneous remission.
Environmental and Occupational Triggers
Occupational exposures to inorganic dusts — silica, beryllium, zirconium, aluminium, and titanium — are associated with granulomatous lung disease that may be indistinguishable from sarcoidosis clinically and histologically. Berylliosis — caused by beryllium exposure in aerospace and electronics manufacturing — mimics sarcoidosis so closely that specific lymphocyte proliferation testing for beryllium sensitivity is sometimes needed to distinguish the two. Agricultural and soil exposures have also been implicated as potential triggers in some populations.
Microbial Antigens
Several lines of evidence suggest that mycobacterial or propionibacterial antigens may trigger the immune response in genetically susceptible individuals — without establishing a viable, replicating infection. This partially explains the overlap between sarcoidosis and TB in clinical presentation and in the positive tuberculin skin test responses sometimes seen in sarcoidosis patients, and why the two conditions are so often confused in high-TB-burden settings like Pakistan.
How Sarcoidosis Presents — The Symptoms
The clinical presentation of sarcoidosis is extraordinarily variable — which is the primary reason it takes so long to diagnose. Some patients have dramatic acute presentations. Others have no symptoms at all and are diagnosed incidentally on a chest X-ray. Most fall somewhere between these extremes.
The most common pulmonary symptoms. Breathlessness typically develops gradually over months and is initially only on exertion. The cough is usually dry and persistent — not productive of significant mucus. In early-stage disease these symptoms may be mild or absent; in advanced fibrocystic disease they can be severely limiting.
Profound fatigue — often out of proportion to the degree of organ involvement — is one of the most consistently reported symptoms in sarcoidosis and one of the most difficult to treat. It reflects the systemic inflammatory burden of active granulomatous disease and significantly impairs quality of life and daily functioning.
Constitutional symptoms including low-grade fever, night sweats, and weight loss occur in active sarcoidosis and are among the features that most closely mimic tuberculosis. They reflect active systemic granulomatous inflammation rather than infection and resolve with corticosteroid treatment rather than antibiotics.
Sarcoidosis affects the skin in approximately 25 percent of patients. Erythema nodosum — tender, raised red nodules typically on the shins — is the most common acute skin manifestation and is associated with a good prognosis. Lupus pernio — violaceous plaques on the nose, cheeks, and ears — indicates chronic disease. Skin biopsy of sarcoid lesions provides an easily accessible tissue diagnosis.
Ocular sarcoidosis occurs in approximately 25 percent of patients — most commonly as anterior uveitis (red, painful eye with photophobia) but also as posterior uveitis, optic neuritis, or lacrimal gland enlargement. Eye involvement can precede lung involvement and should always prompt consideration of systemic sarcoidosis when a thorough ophthalmic assessment reveals uveitis of undetermined cause.
Cardiac sarcoidosis — present in 5 to 10 percent of patients — can cause ventricular arrhythmias, heart block, and sudden cardiac death. It is the most serious extrapulmonary manifestation of sarcoidosis. Palpitations, dizziness, syncope, or an abnormal ECG in a patient with known or suspected sarcoidosis should prompt urgent cardiac evaluation including cardiac MRI.
The patient I most often think of when I consider the cost of misdiagnosis was a young teacher in her thirties who had received three courses of anti-TB treatment over four years. She had never been culture-positive. Her GeneXpert was always negative. She was treated on clinical and radiological grounds alone — and her symptoms never improved. When she finally came to me, a bronchoscopy with biopsy confirmed non-caseating granulomas and no organisms on any staining. She had sarcoidosis. Six weeks of prednisolone cleared her lymphadenopathy and resolved her breathlessness. Four years of unnecessary TB treatment — and the side effects that went with it — could have been avoided with a biopsy at the beginning.
— Dr. Nabila Zaheer, Pulmonologist
Sarcoidosis Versus Tuberculosis — The Critical Distinction
This is the most clinically important section of this article for patients and clinicians in Pakistan. The overlap between sarcoidosis and TB on basic investigations is the primary reason sarcoidosis is so often misdiagnosed — and understanding the distinguishing features is the foundation of getting to the correct diagnosis.
What They Share
Both conditions cause granulomatous inflammation — compact clusters of histiocytes and giant cells — on tissue biopsy. Both can produce enlarged mediastinal lymph nodes visible on chest X-ray and CT. Both cause breathlessness, cough, fever, night sweats, and weight loss. Both can produce a positive tuberculin skin test. Both are more common in younger adults. In Pakistan's clinical context, where TB is the first diagnosis considered for almost any pulmonary abnormality, sarcoidosis simply does not enter the differential diagnosis often enough.
What Distinguishes Them
Key Features Distinguishing Sarcoidosis from Tuberculosis
- Microbiological results — the single most important distinguishing feature. TB is caused by a specific organism that can be identified on sputum smear, GeneXpert, or culture. In sarcoidosis, all microbiological tests — smear, GeneXpert, culture — are consistently negative. A patient with granulomatous disease and consistently negative TB investigations should have sarcoidosis actively considered rather than being treated empirically for TB.
- Biopsy histology — TB granulomas typically show caseating necrosis — a central area of "cheesy" dead tissue surrounded by the granuloma. Sarcoidosis granulomas are non-caseating — compact, "naked" granulomas without central necrosis. This distinction on biopsy is the most reliable pathological differentiator, though caseation can occasionally be absent in TB and occasional caseation can occur in sarcoidosis.
- Response to anti-TB treatment — patients with TB typically improve within two to four weeks of starting anti-TB therapy as the bacterial load falls. Sarcoidosis does not respond to anti-TB drugs. A patient who has received adequate TB treatment for four to six weeks with no clinical or radiological improvement should have the diagnosis questioned and tissue biopsy obtained.
- Serum ACE level — angiotensin-converting enzyme (ACE) is produced by granuloma macrophages and is elevated in approximately 60 percent of active sarcoidosis patients. While not specific enough to diagnose sarcoidosis alone, an elevated serum ACE in the context of consistent clinical and radiological features is a useful supportive finding.
- Calcium levels — hypercalcaemia (elevated blood calcium) or hypercalciuria occurs in approximately 10 to 20 percent of sarcoidosis patients, caused by granuloma-mediated production of active vitamin D. This is characteristic of sarcoidosis and is not seen in TB.
- Multisystem involvement — skin lesions (especially erythema nodosum or lupus pernio), uveitis, salivary gland enlargement, and cardiac involvement all point toward sarcoidosis rather than TB. A patient with enlarged mediastinal lymph nodes and uveitis almost certainly has sarcoidosis.
- Radiological pattern — bilateral hilar lymphadenopathy (bilateral enlargement of the lymph nodes at the lung roots) is the most classic chest X-ray finding of sarcoidosis and is less common in TB, which tends to cause unilateral or asymmetric lymphadenopathy. On HRCT, sarcoidosis typically produces a perilymphatic distribution of nodules — clustered along the bronchovascular bundles and subpleural surfaces — which differs from the random or centrilobular distribution of TB.
Staging and Clinical Course
Pulmonary sarcoidosis is staged radiologically on a scale of 0 to IV, based on the chest X-ray appearance. This staging provides prognostic information and guides treatment decisions.
- Stage 0 — normal chest X-ray. Extrapulmonary sarcoidosis may be present.
- Stage I — bilateral hilar lymphadenopathy without parenchymal lung involvement. The most common presentation at diagnosis, with the highest rate of spontaneous remission (approximately 80 percent).
- Stage II — bilateral hilar lymphadenopathy with pulmonary parenchymal infiltrates. Spontaneous remission occurs in approximately 50 to 60 percent.
- Stage III — parenchymal infiltrates without hilar lymphadenopathy. Spontaneous remission in approximately 30 percent.
- Stage IV — pulmonary fibrosis with architectural distortion, honeycombing, and traction bronchiectasis. This irreversible stage does not remit and is associated with the worst prognosis.
The natural history of sarcoidosis is highly variable. Approximately 60 percent of patients experience spontaneous remission — resolution of the disease without treatment — typically within two to three years of diagnosis. The remaining 40 percent follow a chronic or progressive course requiring long-term management. Stage IV disease, cardiac sarcoidosis, neurosarcoidosis, and multi-organ involvement are the scenarios carrying the greatest risk of serious morbidity and mortality.
How Sarcoidosis Is Diagnosed
Diagnosing sarcoidosis requires the combination of three elements: a compatible clinical and radiological picture, histological confirmation of non-caseating granulomas in a biopsy specimen, and exclusion of other granulomatous conditions — particularly TB and fungal infection — that could produce an identical pathological picture. No single test is sufficient alone.
HRCT of the Chest
High-resolution CT of the chest characterises the distribution and extent of lymphadenopathy and parenchymal involvement. The perilymphatic distribution of nodules, bilateral hilar and mediastinal lymphadenopathy, and the absence of cavitation or tree-in-bud pattern (more typical of TB) provide important differential diagnostic information. HRCT also identifies the optimal biopsy target — the most accessible and most involved area of disease.
Bronchoscopy with Bronchoalveolar Lavage and Transbronchial Biopsy
Bronchoscopy is the primary diagnostic procedure for pulmonary sarcoidosis. Bronchoalveolar lavage (BAL) typically shows an elevated CD4:CD8 lymphocyte ratio — a ratio above 3.5 is highly supportive of sarcoidosis. Transbronchial biopsy — obtaining small lung tissue samples through the bronchoscope — demonstrates non-caseating granulomas in approximately 50 to 70 percent of cases. Endobronchial ultrasound-guided biopsy of mediastinal lymph nodes (EBUS-TBNA) is increasingly available and provides tissue from lymph nodes with high diagnostic yield.
Blood Tests
Serum ACE level, serum calcium, 24-hour urinary calcium, full blood count, liver function tests, and renal function are standard investigations. Elevated ACE supports the diagnosis. Hypercalcaemia or hypercalciuria — characteristic of sarcoidosis — should prompt a dedicated sarcoidosis diagnostic workup.
Additional Investigations for Extrapulmonary Involvement
A 12-lead ECG and Holter monitor screen for cardiac involvement. An ophthalmology referral with slit-lamp examination evaluates for uveitis. Liver ultrasound assesses hepatic involvement. Brain MRI with contrast is indicated when neurological symptoms are present. A comprehensive multisystem assessment ensures that all organ involvement is identified and managed.
Treatment: When Is It Needed and What Works?
Not all sarcoidosis requires treatment — and this is one of the most important management decisions in the condition. Given the high rate of spontaneous remission, treatment is reserved for patients with significant symptoms, progressive disease, or involvement of organs where progression carries serious risk.
Patients with Stage I or Stage II disease who are asymptomatic or have mild symptoms may be managed with watchful waiting — regular clinical and radiological monitoring without pharmacological treatment — given the high probability of spontaneous remission. Follow-up typically includes clinical assessment, chest X-ray or CT, pulmonary function tests, and blood tests at three-to-six-month intervals in the first two years. The decision to observe rather than treat is not passive — it requires active, vigilant monitoring for disease progression.
Corticosteroids — typically prednisolone — are the cornerstone of pharmacological treatment for sarcoidosis requiring intervention. They suppress granulomatous inflammation, reduce lymphadenopathy, improve pulmonary function, and alleviate systemic symptoms. Treatment is typically started at moderate doses (0.5 mg/kg/day) and tapered slowly over six to twelve months, with monitoring for relapse during and after tapering. Corticosteroid treatment does not cure sarcoidosis — it suppresses the inflammation — and relapse is common when treatment is stopped, particularly if it was stopped prematurely.
Patients who require prolonged corticosteroid treatment, who experience significant steroid side effects, or who relapse repeatedly after steroid tapering may benefit from steroid-sparing agents. Methotrexate and azathioprine are the most widely used, reducing the maintenance steroid dose needed while maintaining disease control. Hydroxychloroquine is particularly useful for skin and musculoskeletal sarcoidosis. These medications require regular monitoring for toxicity and should be managed by a specialist experienced in their use.
Certain manifestations of sarcoidosis require urgent, aggressive treatment regardless of disease stage or systemic severity. Cardiac sarcoidosis with arrhythmias or heart block, neurosarcoidosis affecting the brain or spinal cord, and severe posterior uveitis threatening vision all require prompt, high-dose corticosteroid therapy and specialist cardiac, neurological, or ophthalmological co-management. These are the scenarios where delayed diagnosis most directly contributes to serious, irreversible organ damage.
Advanced fibrotic sarcoidosis — Stage IV — does not respond to anti-inflammatory therapy because the fibrosis represents permanent structural change rather than active inflammation. Management focuses on supportive care: bronchodilators for airflow obstruction, long-term oxygen for hypoxaemia, pulmonary rehabilitation for exercise intolerance, and management of pulmonary hypertension where present. In selected younger patients with end-stage fibrotic sarcoidosis, lung transplantation may be considered.
Sarcoidosis requires long-term specialist follow-up because relapse after treatment is common, new organ involvement can appear after initial diagnosis, and the distinction between stable scarring and active inflammation requires periodic reassessment. Annual spirometry, chest imaging at appropriate intervals, serum ACE, calcium, and cardiac screening should form the backbone of ongoing monitoring. Patients who achieve spontaneous remission still benefit from clinical review at two to three years to confirm sustained resolution.
Frequently Asked Questions
I was treated for TB twice and never got better. Could I have sarcoidosis?
Yes — this is one of the most important scenarios in which sarcoidosis should be considered. Tuberculosis treatment produces clear clinical and radiological improvement within four to eight weeks in the vast majority of culture-positive TB patients. A patient who has completed one or more full courses of anti-TB therapy with no improvement — particularly if TB was never confirmed by GeneXpert or culture — should be referred for specialist pulmonology assessment including bronchoscopy and biopsy to evaluate for sarcoidosis and other granulomatous conditions. Years of unnecessary TB treatment does not constitute a trial period for sarcoidosis — it simply delays the correct diagnosis.
Is sarcoidosis contagious? Can I spread it to my family?
No — sarcoidosis is not contagious and cannot be transmitted between people. It is an inflammatory condition driven by immune dysregulation, not an infection caused by a transmissible organism. Family members are at no risk of developing sarcoidosis from contact with an affected person. The slightly elevated familial risk discussed in this article reflects shared genetic factors, not transmission. There is no need for any isolation, precautions, or contact screening of family members on infectious disease grounds.
My ACE level is elevated. Does that mean I have sarcoidosis?
Not definitively — serum ACE elevation is a supportive finding rather than a diagnostic one. ACE can be elevated in other granulomatous conditions including TB, fungal infections, and berylliosis, as well as in some cases of diabetes and hyperthyroidism. Approximately 40 percent of sarcoidosis patients have normal ACE levels, so a normal result does not exclude the diagnosis. An elevated ACE in the right clinical context — bilateral hilar lymphadenopathy, compatible symptoms, negative TB investigations — supports sarcoidosis and should prompt bronchoscopy for tissue confirmation. It should not be used in isolation to diagnose or exclude the condition.
Will sarcoidosis affect my life expectancy?
For the majority of patients, the answer is no. Approximately 60 percent of sarcoidosis patients achieve spontaneous remission with normal or near-normal life expectancy. Even among those requiring treatment, most achieve good disease control with corticosteroids. The minority with serious complications — advanced pulmonary fibrosis, cardiac sarcoidosis with arrhythmias, or severe neurosarcoidosis — carry a more guarded prognosis. Early diagnosis, appropriate specialist management, and vigilant monitoring for cardiac involvement (the leading cause of sarcoidosis-related mortality) are the factors most likely to ensure a good long-term outcome.
How is sarcoidosis different from lymphoma? Both cause enlarged lymph nodes.
This is an important question because both conditions cause mediastinal lymphadenopathy and can present with constitutional symptoms. Lymphoma — particularly Hodgkin lymphoma — is an important differential diagnosis that must be specifically excluded before a diagnosis of sarcoidosis is accepted. Key distinguishing features include: lymphoma typically causes asymmetric or peripheral (cervical, axillary, inguinal) lymphadenopathy in addition to mediastinal nodes, while sarcoidosis preferentially causes bilateral hilar lymphadenopathy; lymphoma does not cause the perilymphatic lung nodules characteristic of sarcoidosis; and biopsy histology definitively distinguishes the two — lymphoma shows malignant lymphoid cells while sarcoidosis shows non-caseating granulomas without malignant cells. PET-CT and tissue biopsy together are definitive when both conditions are in the differential.
An Unexplained Diagnosis Deserves a Second Opinion.
If you have been treated for tuberculosis without confirmed microbiological evidence and your symptoms have not resolved — or if you have enlarged lymph nodes, breathlessness, fatigue, and eye or skin changes that have not been adequately explained — a specialist pulmonology assessment may finally give you the answer you have been waiting for. Book a consultation with Dr. Nabila Zaheer at PulmoCare today.
Book an Appointment